SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced publication of abstracts for three poster presentations at the American Association for Cancer Research (AACR) Annual Meeting. The AACR Annual Meeting Week 1 will be held virtually from April 10-15, 2021. Posters will be available on Harpoon’s website following the presentations.

Full abstracts of the following presentations are available online at www.aacr.org:

Title: FLT3-targeting TriTACs are T cell engagers for treatment of acute myeloid leukemia    
Abstract #: 913
Presenter: Richard J. Austin, Ph.D.
Session Category: Experimental and Molecular Therapeutics
Session Title: PO.ET01.01 - Antibody Technologies
Date/time: April 10, 2021, 8:30 a.m - 11:59 p.m. EDT

Title: ProTriTAC is a modular and robust T cell engager prodrug platform with therapeutic index expansion observed across multiple tumor targets
Abstract #: 933
Presenter: S. Jack Lin, Ph.D.
Session Category: Experimental and Molecular Therapeutics
Session Title: PO.ET01.02 - Biochemical Modulators of the Therapeutic Index
Date/time: April 10, 2021, 8:30 a.m - 11:59 p.m. EDT

Title: Combinatorial antitumor effects of CD3-based trispecific T cell activating constructs (TriTACs) and checkpoint inhibitors in preclinical models
Abstract #: 1573
Presenter: Mary Ellen Molloy, Ph.D.
Session Category: Immunology
Session Title: PO.IM02.02 - Combination Immunotherapies
Date/time: April 10, 2021, 8:30 a.m - 11:59 p.m. EDT

About Harpoon Therapeutics

Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC^®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. HPN424 targets PSMA and is in a Phase 1/2a trial for metastatic castration-resistant prostate cancer. HPN536 targets mesothelin and is in a Phase 1/2a trial for cancers expressing mesothelin, initially focused on ovarian and pancreatic cancers. HPN217 targets BCMA and is in a Phase 1/2 trial for relapsed, refractory multiple myeloma. HPN328 targets DLL3 and is in a Phase 1/2 trial for small cell lung cancer and other DLL3-associated tumors. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. For additional information about Harpoon Therapeutics, please visit www.harpoontx.com.

Contacts:

Harpoon Therapeutics, Inc.
Georgia Erbez
Chief Financial Officer
650-443-7400
media@harpoontx.com

Westwicke ICR
Robert H. Uhl
Managing Director
858-356-5932
robert.uhl@westwicke.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.